Herpes Zoster
Conditions
Interventions
Control Group (Famciclovir Group):orally receive famciclovir at doses adjusted based on creatinine clearance (CrCl), 7 days
Trial Group (Brivudine Group):orally receive brivudine 125 mg per dose, once daily, 7 days
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >=18 years old, gender not limited; 2. Sign the "Informed Consent Form"; 3. Female subjects had no plans to have children or donate eggs from the screening period until one week after the last administration, and voluntarily adopted efficient physical contraceptive measures; Male subjects had no plans to have children or donate sperm from the screening period to one week after the last administration, and voluntarily adopted efficient physical contraceptive measures. Efficient physical contraceptive measures are as follows: (1) Barrier contraception: Condoms or barrier caps (contraceptive films or cervical caps); (2) Place an intrauterine device (IUD) or an intrauterine system (IUS); (3) The subject or his/her sexual partner had undergone surgical sterilization (bilateral ovaries with or without hysterectomy, total hysterectomy, tubal ligation or vas deferens ligation) within 6 months prior to the first use of the study drug; (4) Other reasonable and efficient physical contraceptive measures confirmed by the researcher.
Exclusion criteria
Exclusion criteria: 1. Allergic to brovudine, famciclovir and penciclovir; 2. Currently using fluorouracil drugs (such as 5-fluorouracil, capecitabine, tigafur, flucytosine, etc.); 3. The tumor patient is undergoing chemotherapy; 4. Pregnant and lactating women; 5. Parkinson's disease; 6. The researcher believes that it is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| D30 numeric pain rating scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse Events (AEs) and Serious Adverse Events (SAEs);D3?D7?D14?D90 numeric pain rating scale;Incidence of Postherpetic Neuralgia;The skin lesion conditions on D3, D7, D14, D30 and D90; | — |
Countries
China
Contacts
Public ContactGuo Jinzhu
Peking University Third Hospital
Outcome results
None listed